secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2024-01-26T23:59:59+00:00
Accession:  0001213900-24-006959
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx announces Chair retirement; Lynn O'Connor Vos appointed Chair, Catherine Klema added as director
--------------------------------------------------------------------------------

- Gus Halas retired as Chairperson effective Jan 24, 2024, after nearly a decade of service.
- Lynn O'Connor Vos appointed Chairperson, also joins Nominating & Governance, Compensation, and Audit committees.
- Board increased to 7 members; Catherine M. Klema appointed as director and member of Audit and Compensation committees.
- Klema receives annual cash retainer $40,000, equity grant $150,000, plus additional committee retainers ($10k Audit, $5k Comp).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024006959/0001213900-24-006959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024006959/ea192296-8k_optimizerx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-006959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer